ArticleFrontiers in genetics2025
Development of a prognostic model related to mitochondria and programmed cell death-related genes in bladder cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Various forms of programmed cell death (PCD) play a crucial role in regulating the development and spread of cancer, with mitochondria serving as key organelles involved in executing PCD. In this study, mitochondrial and PCD-related prognostic genes in bladder cancer (BLCA) were explored, and prognostic models were constructed. Methods: The GSE32894, GSE13507, and The Cancer Genome Atlas (TCGA)-BLCA datasets related to BLCA were retrieved. The intersection genes of differentially expressed genes (DEGs) between BLCA and control samples in TCGA-BLCA, mitochondrial-related genes (MRGs), and PCD-related genes (PCD-RGs) were obtained for univariate and multivariate Cox regression analysis. Prognostic genes were selected, and a prognostic model was developed. Then, the validity of the model was evaluated and subsequently validated in the GSE32894 dataset. To enhance the clinical precision of the model, a nomogram was developed and combined with clinical traits. Enrichment analysis, immune infiltration analysis, and drug sensitivity analysis were employed. Finally, the expressions of prognostic genes were verified in the GSE13507 and TCGA-BLCA datasets and by real-time quantitative polymerase chain reaction (RT-qPCR). Results: Based on the above analysis, five prognostic genes ( Conclusion: In this study, a novel prognostic model for bladder cancer was constructed based on POLB, FASN, CASP9, VDAC2, and RHOT2, which provided preliminary references for the prognostic evaluation of bladder cancer and subsequent studies related to its diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.